Johnson & Johnson

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Johnson & Johnson 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About JNJ

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. 

CEO
Joaquin Duato
CEOJoaquin Duato
Employees
139,800
Employees139,800
Headquarters
New Brunswick, New Jersey
HeadquartersNew Brunswick, New Jersey
Founded
1887
Founded1887
Employees
139,800
Employees139,800

JNJ Key Statistics

Market cap
458.62B
Market cap458.62B
Price-Earnings ratio
20.40
Price-Earnings ratio20.40
Dividend yield
2.66%
Dividend yield2.66%
Average volume
8.67M
Average volume8.67M
High today
$191.30
High today$191.30
Low today
$189.00
Low today$189.00
Open price
$189.67
Open price$189.67
Volume
4.10M
Volume4.10M
52 Week high
$192.10
52 Week high$192.10
52 Week low
$140.68
52 Week low$140.68

JNJ News

Seeking Alpha 59m
Protagonist Therapeutics falls amid a report J&J deal price may be lower

Protagonist Therapeutics (NASDAQ:PTGX) dropped 5% after a report that the Johnson & Johnson (NYSE:JNJ) takeover price may be lower than the current share price....

Protagonist Therapeutics falls amid a report J&J deal price may be lower
Benzinga 2h
Johnson & Johnson Q3 Preview: With Stock Near All-Time Highs, Here's What To Watch

Health care giant Johnson & Johnson (NYSE:JNJ) has had a good year with its shares trading near all-time highs. The company looks to keep a trend of beating ana...

Johnson & Johnson Q3 Preview: With Stock Near All-Time Highs, Here's What To Watch
Benzinga 4h
FDA Adds New Warning For Johnson & Johnson's Cancer Cell Therapy

The Food and Drug Administration (FDA) has updated safety labeling for Johnson & Johnson's (NYSE:JNJ) Carvykti after receiving reports of immune effector cell-a...

FDA Adds New Warning For Johnson & Johnson's Cancer Cell Therapy

Analyst ratings

52%

of 25 ratings
Buy
52%
Hold
44%
Sell
4%

More JNJ News

TipRanks 6h
Ardelyx appoints Hohenleitner as Chief Financial Officer

Ardelyx (ARDX) (ADRX) announced the appointment of Sue Hohenleitner as Chief Financial Officer, CFO, effective November 4, 2025. Hohenleitner most recently serv...

Simply Wall St 22h
Is There Still Opportunity in J&J Shares After 32% Rally in 2025?

If you're sizing up what to do with your Johnson & Johnson shares or wondering if now might be the moment to get in, you're not alone. After all, J&J is one of...

Is There Still Opportunity in J&J Shares After 32% Rally in 2025?
The Motley Fool 23h
Douglas Lane Adds $6 Million in J&J Stock Ahead of Earnings and Possible Biotech Deal

Douglas Lane & Associates, LLC disclosed a purchase of 34,948 shares of Johnson & Johnson (JNJ -0.24%) in an SEC filing on Friday, representing an estimated $6...

Douglas Lane Adds $6 Million in J&J Stock Ahead of Earnings and Possible Biotech Deal
Nasdaq 1d
All It Takes Is $2,500 Invested in Each of These 3 High-Yield Dow Dividend Stocks to Help Generate Over $350 in Passive Income per Year

The Dow Jones Industrial Average (DJINDICES: ^DJI) has 30 industry-leading components that act as representatives of the U.S. economy. The index's rich history...

All It Takes Is $2,500 Invested in Each of These 3 High-Yield Dow Dividend Stocks to Help Generate Over $350 in Passive Income per Year
Seeking Alpha 2d
Notable healthcare headlines for the week: Novo Nordisk, Bristol Myers Squibb and J&J in focus

Healthcare Notable healthcare headlines for the week: Novo Nordisk, Bristol Myers Squibb and J&J in focus Oct. 11, 2025 5:45 PM ET The Health Care Select Sector...

Notable healthcare headlines for the week: Novo Nordisk, Bristol Myers Squibb and J&J in focus
Simply Wall St 3d
Johnson & Johnson: Is the Stock Fairly Valued After Its Recent Uptrend?

Johnson & Johnson (JNJ) shares have seen steady gains over the past month, moving up about 8%. The stock’s performance invites a closer look at what is driving...

Johnson & Johnson: Is the Stock Fairly Valued After Its Recent Uptrend?
Nasdaq 3d
Why Protagonist Therapeutics Stock Skyrocketed by Almost 30% Today

Key Points A large, veteran enterprise in the healthcare sector is apparently interested in acquiring it. According to a media report, discussions on a deal a...

Why Protagonist Therapeutics Stock Skyrocketed by Almost 30% Today

People also own

Based on the portfolios of people who own JNJ. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.